Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 13, 2018

SELL
$9.52 - $12.15 $212,572 - $271,297
-22,329 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$6.7 - $12.95 $149,604 - $289,160
22,329 New
22,329 $240,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Amp Capital Investors LTD Portfolio

Follow Amp Capital Investors LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amp Capital Investors LTD, based on Form 13F filings with the SEC.

News

Stay updated on Amp Capital Investors LTD with notifications on news.